⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 24, 2024Journal of the Endocrine SocietyOpen Access

Anastrozole vs Letrozole to Augment Height in Pubertal Males with Idiopathic Short Stature: A 3-Year Randomized Trial

Walter Zegarra Sayali A. Ranadive Diane Toulan E. Kirk Neely

View Full Paper

Ask AI

Bookmark

Share

Abstract

Insufficient efficacy and safety data for off-label use of aromatase inhibitors to augment height in boys with short stature.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zegarra et al. (2024) studied this question.

synapsesocial.com/papers/68e5b027b6db643587549ef2 https://doi.org/10.1210/jendso/bvae141

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Near Final Height in Males treated with Aromatase InhibitorsOriginal Research · 2026 · 1 citations
2Aromatase Inhibitor Effectiveness on Height Augmentation: Optimizing Letrozole Therapy for Height Gain in Short-Statured Boys2025
3Anastrozole monotherapy further improves near-adult height after the initial combined treatment with leuprorelin and anastrozole in early-maturing girls with compromised growth prediction: results from the second phase of the GAIL study2024
4Impact of Aromatase Inhibition on Bone Mineral Density and Structure: A Randomized Controlled Trial in Boys With Delayed Puberty2025 · 1 citations
5Efficacy and safety of aromatase inhibitors in the management of idiopathic short stature: A meta-analysis2024 · 2 citations